FLASH proton therapy preserved ocular function without reducing short-term tumor control
FLASH protons largely preserved ocular structure and retinal function after 24 Gy while maintaining short-term tumor control in mice.
Tag
preliminary
Spatially fractionated radiotherapy relieved symptoms in most patients with bulky tumors
Spatially fractionated radiotherapy relieved symptoms in 91.7% of patients with bulky advanced tumors without reported grade ≥3 toxicity.
Hybrid FLASH preserved normal-tissue sparing when the ultra-high-rate dose remained high
Hybrid ultra-high and conventional dose-rate irradiation retained FLASH sparing in mice, but protection diminished as the ultra-high-rate dose contribution decreased.
Yttrium-90 radioembolization produced durable hepatic responses in SDH-deficient GIST
Yttrium-90 radioembolization achieved 67% objective response and 100% disease control in 12 patients with SDH-deficient GIST liver metastases.
Age and comorbidity identified poor prognosis in elderly patients receiving esophageal chemoradiotherapy
Patients aged ≥75 years with CIRS-G ≥7 had median overall survival of 16 months after definitive chemoradiotherapy.
Early response-adapted TNT preserved the rectum in a minority of selected patients
Two-year sustained complete response was 36% after short-course RT and response-adapted FOLFOX4, while near-complete responses frequently regrew.
Third-course reirradiation provided symptom relief in selected patients with progressive DIPG
Across 12 reported patients receiving at least three radiation courses for DIPG, median survival was 27 months with frequent symptomatic benefit.
Berberine increased radiation-induced DNA damage and tumor suppression in HNSCC models
Berberine enhanced radiation response in HNSCC models by increasing DNA damage and apoptosis while suppressing DNA repair and stemness pathways.
Single-fraction lung SBRT achieved 100% estimated one-year local control in selected patients
Single-fraction SBRT achieved 100% estimated 12-month local control without grade ≥3 toxicity in a selected 49-patient cohort.
Neoadjuvant chemotherapy shifted HR+/HER2− breast tumors toward higher genomic radioresistance
RSI increased after neoadjuvant chemotherapy in 23 of 30 matched HR+/HER2− tumors, but implications for adjuvant radiation dose remain unproven.
Heterogeneous EclipseRT plus PD-1 therapy was feasible in nine bulky NSCLC patients
EclipseRT plus PD-1 blockade produced five responses among nine bulky NSCLC patients without grade ≥3 treatment-related toxicity.
Severe brainstem necrosis followed standard proton CSI in 22q11.2 deletion syndrome
A patient with 22q11.2 deletion developed refractory brainstem necrosis nine months after guideline-concordant proton craniospinal irradiation.
Iodine-125 brachytherapy preserved lung function in high-risk NSCLC patients
CT-guided iodine-125 implantation achieved 60.7% one-year response without grade ≥3 pneumonitis in patients with severe pulmonary dysfunction.
Immune-rich rectal tumors responded better to neoadjuvant radiotherapy than stromal-rich tumors
Responsive rectal tumors showed greater cytotoxic immune infiltration, while poor responders were enriched for stromal, EMT and oncogenic pathways.
Radiomic shape features improved xerostomia prediction after nasopharyngeal radiotherapy
Adding parotid–target overlap shape features improved moderate-to-severe xerostomia prediction from AUC 0.66 to 0.78.